Seely Lynn sold $149K of LYEL
Seely Lynn (President and CEO) sold 9,589 shares of Lyell Immunopharma, Inc. (LYEL) at $15.54 ($0.15M total) on 2026-08-21.
How this was made
The 30-second read
Why it matters
The insider sale is routine and unlikely to affect LYEL's price; investors may monitor for larger future disposals.
Market read
A small insider sell by the CEO; minimal relevance for traders.
What to watch
Potential upcoming corporate actions or financing needs not disclosed in the filing.
Background
SEC Form 4 filing discloses insider transactions; required to be filed within two business days of the trade.
Ticker impact
CEO Seely Lynn sold 9,589 shares for $149,013 on 2026-08-21, reducing his stake to 63,899 shares.
No significant price impact expected.
The sale size is small relative to market cap and typical insider trading volumes; market typically views such routine sales as non‑material.
Market effects
None; the transaction is company‑specific and does not affect the biotech sector.
None; the filing is a US‑listed company with no broader regional effect.
None
Counterpoint
If the CEO is reducing exposure, it could signal concerns, but the amount is too small to be meaningful.
Key entities
- CompanyLyell Immunopharma, Inc.
Biotech company developing immunotherapies, ticker LYEL.
- ExecutiveSeely Lynn
President and CEO of Lyell Immunopharma.